MetroWest495 Biz

Last year, the company, which was founded in Israel in 2001 and opened its Marlborough operations in 2012, hit some impressive milestones. In May, it received the Smaller Business Association of New England's Innovation Award. A month later, the ReWalk exoskeleton became the first product of its kind to get FDA approval. In September, the company completed a $150 million initial public offering. In 2015 and beyond, ReWalk is poised for even bigger things. Observers see its products finding a huge market, and doing great things for people with disabilities. The big question is whether the company can stay ahead of competi- tors as the fledgling exoskeleton industry explodes. Matthew Taylor, an analyst who follows ReWalk for Barclays, said one thing that stands out about the company's devices is what patients and doctors have to say about them. 12 MetroWest495 Biz | February 2015 Marlborough robotic exoskeleton company is the fastest-moving player in a huge market P H O T O S / C O U R T E S Y ReWalk goes for the big time BY LIVIA GERSHON T alk to technology entrepreneurs and there's a question that often comes up: Would you rather do cool stuff or important stuff? Make an amazing virtual reality headset or improve the treatment options for diabetes? ReWalk Robotics doesn't have to choose. The company, which has its U.S. headquarters in Marlborough, makes something straight out of the comic books — robotic exoskeletons — and uses them to do something amazing: help paraplegics walk again. P H O T O / E D D C O T E FOCUS: Health Care ReWalk Robotics CEO Larry Jasinski displays a ReWalk system at the company's U.S. headquarters in Marlborough in February. Above right: Company images show ReWalk exoskeletons helping paraplegic patients walk again.

• Cover